Rare diseases
Investigational molecules
Locations
Back to Czechia1 218 clinical trials in Prague, Czechia across 18 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.
Our site in CzechiaKlinickeTesty.cz(opens in a new tab)Study on Midostaurin and Chemotherapy for Children with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia
CzechiaStudy on the Safety and Effectiveness of TIN816 for Patients with Sepsis-Related Acute Kidney Injury
CzechiaStudy on the Effectiveness and Safety of CAEL-101 with Drug Combination for Patients with Advanced AL Amyloidosis
CzechiaStudy on Niraparib for Maintenance Treatment in Patients with Advanced Ovarian Cancer After Initial Chemotherapy Response
CzechiaStudy on the Safety and Effectiveness of Epcoritamab, Venetoclax, and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome
CzechiaStudy on the Long-Term Safety of Povorcitinib for Patients with Moderate to Severe Hidradenitis Suppurativa
CzechiaStudy Comparing Subcutaneous and Intravenous Isatuximab with Pomalidomide and Dexamethasone for Adults with Relapsed or Refractory Multiple Myeloma
CzechiaStudy on the Safety and Effectiveness of Tovinontrine for Adults with Chronic Heart Failure with Reduced Ejection Fraction
CzechiaStudy Comparing Selpercatinib, Cabozantinib, and Vandetanib for Patients with Advanced RET-Mutant Medullary Thyroid Cancer
CzechiaStudy on the Effectiveness and Safety of ND0612 Infusion vs. Oral Treatment for Parkinson's Disease Patients with Motor Fluctuations
CzechiaStudy of Secukinumab for Maintaining Remission in Patients with Non-Radiographic Axial Spondyloarthritis
CzechiaStudy on the Effectiveness and Safety of Belzupacap Sarotalocan for Patients with Small Choroidal Melanoma or Indeterminate Lesions
CzechiaThe busiest research cities in the country
What the registry says about research in the country
Clinical trial activity in Praha includes research in advanced melanoma and diffuse large B-cell lymphoma, with a strong focus on improving cancer control and extending survival.
These studies are designed to refine how immunotherapy and other cancer treatments perform in everyday clinical care.
Research in cardiovascular diseases is centered on reducing major heart and vascular events, with trials looking at hypertension, atherosclerotic cardiovascular disease, and heart failure prevention.
Several studies aim to improve treatment effectiveness for patients at elevated cardiovascular risk.
Trials in the respiratory field focus on better symptom control and fewer flare-ups in chronic obstructive pulmonary disease, alongside ongoing work in infection-related lung illness.
These studies support more effective care for both chronic and acute respiratory conditions.
Dermatology research in Czechia includes several inflammatory skin disorders, with studies targeting itch, lesion control, and long-term disease management.
The goal is to evaluate new therapies that may ease symptoms and improve quality of life.
Studies in immune-mediated disease are exploring treatments that can calm abnormal inflammation while maintaining safety and tolerability.
These trials aim to improve control of chronic immune-driven disease burden.
Neurology-related research focuses on agitation in Alzheimer's disease dementia, with efforts to better manage behavioral symptoms that affect patients and caregivers.
These studies may help support more practical care for people living with dementia.
Metabolic research in Praha includes trials for overweight, obesity, and related conditions, often linked with cardiovascular risk.
These studies are testing approaches that may help reduce long-term health risks tied to excess weight.
In the area of virus diseases, research is centered on improving treatment options for people with COVID-19 who are at higher risk of becoming seriously ill.
The main aim is to help prevent worsening disease and support faster recovery.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
